CD36 and cancer: Wang et al. (2020) found selective upregulation of CD36 in intra-tumoral Treg cells in both human cancers and preclinical murine tumor models. Using an elegant Treg-specific CD36 deletion model, they demonstrated selective abrogation of abundance and suppressive activity of intra-tumoral Treg cells. Targeting CD36 with a mAb also diminished Treg-mediated immunosuppression and CD36 blockade, either alone or in combination with anti–PD-1 treatment, and induced enhanced antitumor immunity (Wang et al., 2020; Fig. 3 A).